期刊
ANTIVIRAL THERAPY
卷 20, 期 2, 页码 109-120出版社
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP2824
关键词
-
资金
- Wellcome Trust Centre for Mitochondrial Research [096919Z/11/Z]
- Medical Research Council (UK) Centre for Translational Muscle Disease research [G0601943]
- EU FP7 TIR-CON
- National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle-upon-Tyne Hospitals NHS Foundation Trust
- Newcastle University
- Medical Research Council, UK [G0800470]
- AstraZeneca
- MRC [G0601943, G0800470, MR/K000608/1] Funding Source: UKRI
- Academy of Medical Sciences (AMS) [AMS-SGCL12-Payne] Funding Source: researchfish
- Medical Research Council [MR/K000608/1, G0800470, G0601943] Funding Source: researchfish
- National Institute for Health Research [CL-2013-01-004] Funding Source: researchfish
Mitochondrial DNA (mtDNA) mutations cause neurological and multisystem disease. Somatic (acquired) mtDNA mutations are also associated with degenerative diseases and with normal human ageing. It is well established that certain nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral drugs cause inhibition of the mtDNA polymerase, pol gamma, leading to a reduction in mtDNA content (depletion). Given this effect of NRTI therapy on mtDNA replication, it is plausible that NRTI treatment may also lead to increased mtDNA mutations. Here we review recent evidence for an effect of HIV infection or NRTI therapy on mtDNA mutations, as well as discussing the methodological challenges in addressing this question. Finally, we discuss the possible implications for HIV-infected persons, with particular reference to ageing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据